Background: Sodium glucose transporter 2 (SGLT-2) inhibitors are a relatively new group of antidiabetic drugs. The renal glucose reabsorption is blocked resulting in higher glucose levels in the urine (glucosuria). Recently studies are being conducted into the medications nephrological and cardiovascular potential. As a result, we may expect that SGLT-2 inhibitors will be more and more frequently prescribed. Thus, physicians of any specialty may come into contact with patients that are using this drug.
Case Description: We describe a case of a male patient who developed a urinary tract infection with Candida glabrata while using a SGLT-2 inhibitor. After discontinuing the SGLT-2 inhibitor, the infection subsided.
Conclusion: Urinary tract infections from Candida are rarely seen in healthy individuals. Glucosuria is a known risk factor for fungal genital infections. More research is needed to determine whether SGLT-2 inhibitors increase the risk of fungal urinary tract infections.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Age-dependent effects of SGLT2 inhibitors on stroke risk in geriatric patients with diabetes and atrial fibrillation.
Cardiovasc Diabetol
January 2025
Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital, Taipei City, Taiwan, ROC.
Background: Atrial fibrillation (AF) and diabetes mellitus (DM) are associated with an increased risk of ischemic stroke, particularly in geriatric populations. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have demonstrated cardiovascular benefits, but their effects on stroke risk may vary by age. This study aimed to explore the age-dependent effects of SGLT2i on stroke risk in patients with AF and DM.
View Article and Find Full Text PDFAssociation of sodium-glucose cotransporter-2 inhibitors with mortality across the spectrum of myocardial infarction: a systematic review and meta-analysis.
Cardiovasc Diabetol
January 2025
Department of Internal Medicine B, University of Medicine Greifswald, Ferdinand-Sauerbruch-Straße, 17475, Greifswald, Germany.
Background: The impact of sodium-glucose cotransporter-2 (SGLT2) inhibitors on mortality following myocardial infarction (MI) remains uncertain. Additionally, the role of type 2 diabetes mellitus (T2DM) and heart failure (HF) in modulating the effectiveness of these drugs post-MI are not fully understood. This meta-analysis aimed to assess the association of SGLT2 inhibitors with all-cause mortality in post-MI patients and to explore key moderators influencing this benefit.
View Article and Find Full Text PDFDapagliflozin plus calorie restriction for remission of type 2 diabetes: multicentre, double blind, randomised, placebo controlled trial.
BMJ
January 2025
Ministry of Education Key Laboratory of Metabolism and Molecular Medicine, Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China.
Objective: To assess the effect of dapagliflozin plus calorie restriction on remission of type 2 diabetes.
Design: Multicentre, double blind, randomised, placebo controlled trial.
Setting: 16 centres in mainland China from 12 June 2020 to 31 January 2023.
Association between use of sodium-glucose co-transporter-2 inhibitor and the risk of incident dementia: a population-based cohort study.
BMJ Open Diabetes Res Care
January 2025
Lady Davis Institute for Medical Research Centre for Clinical Epidemiology, Montreal, Québec, Canada
Objectives: To assess the association between sodium-glucose co-transporter-2 inhibitor (SGLT-2i) use and the risk of incident dementia compared with dipeptidyl peptidase-4 inhibitors (DPP-4i) use among individuals with type 2 diabetes.
Design: A population-based retrospective cohort study.
Setting: The Clinical Practice Research Datalink (CPRD) Aurum database from the UK.
Use of Potentially Nephrotoxic Drugs in Type 2 Diabetes Patients on SGLT2i: A Trajectories Analysis.
Pharmacoepidemiol Drug Saf
February 2025
Division of Clinical Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California, USA.
Purpose: To characterize trajectories of nephrotoxic potential (NxP) drug use among older adults with Type 2 Diabetes (T2D) treated with SGLT2is and identify associated patient characteristics.
Methods: Using 2012-2019 Medicare data, we selected patients with T2D who filled at least one prescription for SGLT2is. Index date was the date of the first SGLT2i prescription filled.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!